← Back to Patent Explorer
US4430502A Expired / Lapsed US ⏱️ 0.0 years remaining

Pyridinyl substituted benzimidazoles and quinoxalines

Assignee: SDS Biotech Corp
•
Filing: 1982-08-13
•
Granted: 1984-02-07
•
Expires: 2002-08-13
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention provides novel pyridinyl-benzimidazoles and quinoxalines which are useful as thromboxane A 2 (TXA 2 ) synthetase inhibitors and as such represent potent pharmacological agents.

Inventors

  • 👤 Norman A. Nelson

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 08:09
CPC Classifications
C; C07; C07D; C07D213/00; C07D213/02; C07D213/04; C07D213/24; C07D213/44; C07D213/53; A; A61; A61P; A61P1/00; A61P1/04; A61P29/00; A61P35/00; A61P43/00; A61P7/00; A61P7/02; A61P9/00; A61P9/12; C07D401/00; C07D401/02; C07D401/06; C07D401/12

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 208 words
A compound of the formula I or II wherein Z 1 is (a) 4-pyridinyl, (b) 3-pyridinyl, or (c) 3-pyridinyl substituted by (C 1 -C 4 )alkyl; wherein X 1 is (a) --(CH 2 ) n-- , (b) --O--, (c) --CH 2 --O--, or (d) --O--CH 2 --; wherein Y 1 is --(CH 2 ) m --R 7 ; wherein R 1 is hydrogen, a pharmacologically acceptable cation, (C 1 -C 12 ) alkyl, (C 3 -C 10 ) cycloalkyl, (C 7 -C 12 ) aralkyl, phenyl, phenyl mono-, di-, or trisubstituted by chloro, or (C 1 -C 3 ) alkyl, or phenyl para-substituted by (a) --NHCO--R 25 , (b) --O--CO--R 26 , (c) --CO--R 24 , (d) --O--CO--(p--Ph)--R 27 , or (e) --CH═N--NH--CO--NH 2 , wherein R 24 is phenyl or acetamidophenyl, R 25 is methyl, phenyl, acetamidophenyl, benzamidophenyl, or amino, R 26 is methyl, phenyl, amino or methoxy; and R 27 is hydrogen or acetamido, and wherein --(p--Ph) is 1,4-phenylene; wherein R 7 is (a) --CH 2 OH, (b) --CHO, or (c) --COOR 1 ; wherein m is an integer of from 0 to 4; and n is an integer of from 1 to 3, inclusive; including, pharmacologically acceptable acid addition salts thereof, and tautomeric forms thereof.
Claim 2
Dependent Claim 208 words
A compound of the formula I or II wherein Z 1 is (a) 4-pyridinyl, (b) 3-pyridinyl, or (c) 3-pyridinyl substituted by (C 1 -C 4 )alkyl; wherein X 1 is (a) --(CH 2 ) n-- , (b) --O--, (c) --CH 2 --O--, or (d) --O--CH 2 --; wherein Y 1 is --(CH 2 ) m --R 7 ; wherein R 1 is hydrogen, a pharmacologically acceptable cation, (C 1 -C 12 ) alkyl, (C 3 -C 10 ) cycloalkyl, (C 7 -C 12 ) aralkyl, phenyl, phenyl mono-, di-, or trisubstituted by chloro, or (C 1 -C 3 ) alkyl, or phenyl para-substituted by (a) --NHCO--R 25 , (b) --O--CO--R 26 , (c) --CO--R 24 , (d) --O--CO--(p--Ph)--R 27 , or (e) --CH═N--NH--CO--NH 2 , wherein R 24 is phenyl or acetamidophenyl, R 25 is methyl, phenyl, acetamidophenyl, benzamidophenyl, or amino, R 26 is methyl, phenyl, amino or methoxy; and R 27 is hydrogen or acetamido, and wherein --(p--Ph) is 1,4-phenylene; wherein R 7 is (a) --CH 2 OH, (b) --CHO, or (c) --COOR 1 ; wherein m is an integer of from 0 to 4; and n is an integer of from 1 to 3, inclusive; including, pharmacologically acceptable acid addition salts thereof, and tautomeric forms thereof.
Claim 3
Dependent Claim 52 words
A compound of claim 1 of the formula I, wherein Y 1 is --(CH 2 ) m R 7 , m is zero, X 1 is --(CH 2 ) n wherein n is one, or --O--, Z 1 is 3-pyridinyl, and R 7 is --COOR 1 , --CH 2 OH, or --CHO.
Claim 4
Dependent Claim 6 words
2-Hydroxymethyl-5-(3-pyridinylmethyl)benzimidazole, a compound of claim 2.
Claim 5
Dependent Claim 6 words
2-Formyl-5-(3-pyridinylmethyl)benzimidazole, a compound of claim 2.
Claim 6
Dependent Claim 19 words
A compound of claim 2, wherein X 1 is --CH 2 -- and R 7 is --COOR 1 .
Claim 7
Dependent Claim 6 words
2,3-Dihydroxy-6-(3-pyridinylmethyl)quinoxaline, a compound of claim 1.
Claim 8
Dependent Claim 9 words
5-(3-Pyridinylmethyl)benzimidazole-2-carboxylic acid, ammonium salt, a compound of claim 2.

References Cited (Backward Citations)

DE2537837A1 Cited
US4026936A Cited
US4032536A Cited
US4112224A Cited
US4259338A Cited
US4335132A Cited
US4331671A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-02-06 1987-08-08 1988-02-07 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-02-06 1991-08-08 1992-02-07 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-02-06 1995-08-08 1996-02-07 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag